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Erythropoiesis describes the hematopoietic process of cell proliferation and diﬀerentiation that results in the production of mature
circulating erythrocytes. Adult humans produce 200 billion erythrocytes daily, and approximately 1 billion iron molecules are
incorporated into the hemoglobin contained within each erythrocyte. Thus, iron usage for the hemoglobin production is a
primary regulator of plasma iron supply and demand. In many anemias, additional sources of iron from diet and tissue stores
are needed to meet the erythroid demand. Among a subset of anemias that arise from ineﬀective erythropoiesis, iron absorption
and accumulation in the tissues increases to levels that are in excess of erythropoiesis demand even in the absence of transfusion.
The mechanisms responsible for iron overloading due to ineﬀective erythropoiesis are not fully understood. Based upon data that
is currently available, it is proposed in this review that loading and overloading of iron can be regulated by distinct or combined
mechanisms associated with erythropoiesis. The concept of erythroid regulation of iron is broadened to include both physiological
and pathological hepcidin suppression in cases of ineﬀective erythropoiesis.
1.Introduction
In the absence of blood transfusions, hereditary mutations
play the primary role in most syndromes of iron over-
load [1]. The genetic bases for several inherited forms of
hemochromatosis were identiﬁed and experimentally con-
ﬁrmedasgenesinvolvedinironregulation.Thesediscoveries
subsequently led to major advances in understanding iron
biology [2]. Distinct from iron-regulating genes and their
products, a group of erythroid disorders that demonstrate
ineﬀective erythropoiesis also manifest a hemochromatosis
phenotype. While tissue iron overload is a shared feature of
these erythroid disorders, there is no evidence for a shared
genetic mutation. Instead, the ineﬀective erythropoiesis itself
seems to cause iron accumulation and eventual overload.
Iron loading in the liver and other tissues proceeds well
beyond the levels needed to support erythropoiesis. Based
upon mapping of the human genome and the discovery of
hepcidin, new mechanisms are being explored for physio-
logical and pathological regulation of iron associated with
ineﬀective erythropoiesis.
2. UnderstandingIneffective Erythropoiesis
Erythrocytes serve a major function of oxygen transport
and delivery throughout the body. Erythrocyte production
is appropriately driven by inadequate delivery of oxygen
to the tissues. The reduced tissue oxygen levels are sensed
by peritubular cells in the renal cortex and outer medulla
[3]. In response, those kidney cells express and secrete
erythropoietin (EPO) [4]. Plasma EPO is transported to the
bone marrow in order to promote the production of new
erythrocytes. The new erythrocytes are produced through
the process whereby erythroblasts respond to erythropoietin
viaproliferationanddiﬀerentiationoverthecourseofseveral
days. During erythropoiesis, large amounts of iron are
needed to produce hemoglobin. Importantly, transferrin-
bound iron is endocytosed into erythroblasts after binding
to the plasma membrane receptors [5–8]. High levels
of membrane transferrin receptors are maintained during
each cell cycle and at each stage of nucleated erythroblast
diﬀerentiation [9]. As the iron demands are met, iron uptake
is decreased due to reduced transferrin receptor expression2 Advances in Hematology
during the terminal diﬀerentiation of the cells. Ultimately,
hemoglobin production ceases, as does the demand for iron.
In a concerted fashion, the transferrin receptor is released
from the plasma membranes of reticulocytes as one of the
ﬁnal steps of erythroid diﬀerentiation [10].
Ineﬀective erythropoiesis describes a group of erythroid
disorders that produce fewer numbers of erythrocytes than
wouldbeexpectedtoarisefromthelessmatureerythroblasts
present in the marrow. As a result, there exists an imbalance
between the amount of iron that is endocytosed by the
marrow erythroblasts and the amount of iron released
into the circulation in erythrocytes [11, 12]. The concept
of ineﬀective erythropoiesis grew from ferrokinetic studies
[13]. Classic ferrokinetic studies distinguished the patterns
of iron utilization during ineﬀective erythropoiesis from
aplastic anemia, hemorrhage, or peripheral hemolysis [12].
In addition to ferrokinetics, more recent research was
focuseduponidentifyingmolecularandcellularmechanisms
that cause the underlying erythroid defects [14].
The erythroid response to tissue hypoxia is fundamental
for understanding the pathophysiology of ineﬀective ery-
thropoiesis. Tissue hypoxia is a common feature of anemias.
Tissue hypoxia increases the expression of erythropoietin,
andtheerythropoietindrivestheproductionofnewerythro-
cytes. In cases of anemia associated with ineﬀective erythro-
poiesis, imbalance between erythrocyte supply and demand
persists despite increased tissue hypoxia and increased
erythropoietin.Asaresult,erythropoietinlevelsremainhigh,
and the marrow of patients with ineﬀective erythropoiesis
typically becomes hypercellular [15–17]. Over the course
of time, the combination of tissue hypoxia, increased ery-
thropoietin, and ineﬀective erythropoiesis creates a vicious
cycle that may ultimately lead to a massive expansion of
erythroblasts. Eventually, secondary bony pathologies [18]
and extramedullary erythropoiesis [19] can also develop. Per
the topic of this review, pathological iron overload in the
absence of hereditary hemochromatosis is another hallmark
of the disease.
Several types of erythroid defects cause signiﬁcant tissue
iron overload in association with ineﬀective erythropoiesis.
The major entities are summarized in Table 1. The tha-
lassemiasyndromes(thalassemiamajorandintermedia)rep-
resent the most common causes of ineﬀective erythropoiesis.
In the thalassemia syndromes, imbalances in the production
ofalpha-andbeta-globinchainsresultinincreasedapoptosis
during erythroblast maturation [14]. Iron loading, even in
the absence of transfused blood, is a well-recognized com-
plication of the disease [20]. In sideroblastic anemias, globin
chainproductionisintact,buterythropoiesisischaracterized
by accumulation of iron in mitochondria that “ring” the
erythroblastnucleusduringmaturation[21].Intramedullary
apoptosis is a feature of acquired sideroblastic anemia [22].
Some genes that regulate mitochondrial iron metabolism
also cause the inherited form of sideroblastic anemia [23].
Since the inherited mitochondrial defects are not neces-
sarily limited to hematopoietic cells, tissue iron loading in
those patients may not be derived solely from ineﬀective
erythropoiesis[24].However,thespecializationofiron,iron-
sulfur,andhemetraﬃckinginerythroblastsstronglysuggests
Table 1: Ineﬀective erythropoiesis associated with iron overload in
absence of transfusion.
Erythroid disorder Defect Reference
Thalassemia syndromes Globin chain
imbalance.
[67, 86]
Sideroblastic Anemia
(inherited or acquired)
Iron accumulation in
mitochondria.
[23, 70, 87, 88]
Dyserythropoietic Anemia
(Types I and II)
Nuclear and
membrane defects.
[26, 27, 69]
erythroid involvement in the iron loading pathology. As
recently reviewed by Sheftel et al., ringed sideroblasts are
associated with several erythroblast iron and mitochondrial
defects [25]. It remains to be determined whether separate
defects that result in sideroblastic anemia have equivalent
eﬀects upon iron homeostasis in nonerythroid tissues. A
third group of disorders associated with ineﬀective erythro-
poiesis and iron overloading are called dyserythropoietic
anemias[26].Thedyserythropoieticdefectsaredistinctfrom
others in mutations of globin and mitochondrial genes
[26, 27]. Tissue iron overload is not uncommon in two
of three dyserythropoietic subtypes. Pyruvate kinase deﬁ-
ciency results in defective glycolysis resulting in erythroblast
apoptosis and peripheral blood hemolysis [28, 29]. Pyruvate
kinase deﬁciency is being investigated as a separate cause of
ineﬀective erythropoiesis, but iron overloading is less con-
sistent among these patients [30]. Other erythroid disorders
associated with some degree of ineﬀective erythropoiesis
include chronicpernicious anemia,hereditary spherocytosis,
and sickle cell anemia [31, 32]. However, the association
between iron loading and ineﬀective erythropoiesis in these
disorders is inconsistent [33].
3. IronLoadingandOverloadingin
IneffectiveErythropoiesis
Adult humans produce approximately 200 billion erythro-
cytes daily [34]. Each erythrocyte contains approximately
300millionmoleculesofhemoglobin[35].Eachhemoglobin
molecule contains four heme molecules, and each heme
contains a single iron moiety. Therefore, to satisfy the
production of erythrocytes, 2 E20 iron molecules (20mg)
are utilized daily for erythropoiesis even in the absence of
disease. The robust demand for iron is met by transferrin-
bound iron in the plasma [36] .T h r e em a j o rs o u r c e so f
iron are utilized to maintain adequate levels of transferrin-
bound iron: dietary iron, body iron stores, and recycled iron
from senescent erythrocytes. In healthy adults, the majority
of transferrin-bound iron in the plasma is generated from
macrophagecatabolismofmatureerythrocytesincirculating
blood. In steady state, the iron that is recycled from older
erythrocytes is largely suﬃcient for the production of new
erythrocytes. Phagocytosis of the older erythrocytes by
macrophages results in their catabolism and the breakdown
of hemoglobin. The hemoglobin-salvaged iron is loaded
on transferrin for transport to marrow erythroblasts. TheAdvances in Hematology 3
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Figure 1: The hemoglobin iron cycle
membrane expression of ferroportin, an iron channel pro-
tein, provides the key regulatory element of transferrin
loading of iron from macrophages. Ferroportin levels on
the cell membrane are regulated by another protein named
hepcidin. Hepcidin acts through binding and internalization
of ferroportin from the surface of iron-exporting cells
[37–39]. Therefore, hepcidin is a principal regulator of
the hemoglobin iron cycle. Hepcidin expression is highly
regulated by a growing number of proposed mechanisms. In
the steady state, broad variations in plasma levels of hepcidin
are predicted among adults [40]. In iron deﬁcient states,
hepcidin expression is consistently suppressed. In ineﬀective
erythropoiesis, hepcidin expression is less consistently sup-
pressed [41].
In a variety of conditions, the hemoglobin iron cycle
(Figure 1) becomes unbalanced due to a decreased supply of
iron from mature erythrocytes or an increased erythroblast
demand.Inmostcasesofanemia,theimbalanceismagniﬁed
by tissue hypoxia with increased erythropoietin production.
If the supply of iron from aging erythrocytes is inadequate,
transferrin-bound iron must be obtained from tissue stores
and the diet [42]. Increased transferrin iron loading from
multiple sources is achieved when hepcidin is suppressed
[43]. Erythroblast demand for iron continues until tissue
demands for oxygen are satisﬁed, and iron stores are replen-
ished. As shown in Table 2, several erythroid disorders are
associated with imbalances between tissue hypoxia, erythro-
poietin, and erythropoiesis. With the exception of aplastic
anemia, the erythroblast demand for iron is increased. It is
presumed that hepcidin expression is reduced to meet the
erythroblast demand in many, if not all of these disorders,
but conﬁrmatory studies are awaited. Despite the erythroid
demand for iron, extra-erythroid loading of iron is not
a typical feature of anemia or polycythemia. Remarkably,
ineﬀective erythropoiesis is unique in causing accumulation
of iron in extra-erythroid tissues to levels that are well
beyond the erythroid requirements.
4.How Does IneffectiveErythropoiesisCause
Tissue IronOverload?
Iron absorption is normally regulated by a combination
of iron stores, inﬂammation, hypoxia, and erythropoietic
iron demand [44, 45]. Presumably, the mechanisms that
satisfy the iron appetite of immature erythroblasts are also
active in ineﬀective erythropoiesis. Those molecular and
cellular mechanisms are a focus of curiosity- and clinical-
driven hematology research [46]. Along with a physiolog-
ical mechanism that provides a basis for the erythroid
regulator of iron, it is proposed here that pathological
mechanisms may be identiﬁed that are unique to ineﬀective
erythropoiesis. The notion of a pathological iron regulator
is suggested by the unique accumulation of iron to toxic
levels in patients with ineﬀective erythropoiesis. As discussed
below, the cytokine named GDF15 could serve the role of a
pathological erythroid signal. Since hepcidin plays a central
role in that network, the discussion here is largely focused
upon erythroid-related variables, including GDF15, which
may contribute to suppressed expression of hepcidin.
4.1. Iron, Iron Transport, and Iron Turnover. For many
years, plasma iron parameters or the depletion of iron from
the plasma compartment were actively investigated as the
mechanism of signaling between erythropoiesis and iron
regulation [47, 48]. Recently, it was reported that hepcidin
expression correlates with transferrin saturation levels [49].
While decreased transferrin saturation could provide a
mechanism for hepcidin suppression in iron deﬁcient states,
it seems less likely that the transferrin saturation levels
detected in ineﬀective erythropoiesis (sometimes 100%)
causesuppressionofhepcidin.Inadditiontohightransferrin
saturation levels, there is an overall increase of holo-
transferrin removal from the plasma for iron delivery to the
expanded population of immature erythroblasts. Increased
plasma iron turnover is increased in humans with ineﬀective
erythropoiesis [50]. In addition, the newly incorporated
iron is recycled from marrow erythroblasts rather than
circulating erythrocytes. While increased plasma delivery
and erythroblast recycling of iron from the erythropoietic
compartment are interesting components of ineﬀective ery-
thropoiesis, the signiﬁcance of these features in suppression
of hepcidin remains uncertain. Transferrin metabolism,
saturationkinetics,plasmaironturnover,andhemerecycling
are all complex processes [48]. The topic remains unsettled.
4.2. Hypoxia and Erythropoietin in Ineﬀective Erythropoiesis.
Tissue hypoxia directly inhibits hepcidin expression in
hepatocytes. Hypoxia eﬀects are generally independent of
iron stores [46]. Since patients with severe ineﬀective
erythropoiesis are usually anemic, tissue hypoxia may play
a role in iron regulation in this disorder. Comparative
data between hepatocyte cell lines and nonanemic animals
exposed to hypoxic conditions consistently demonstrated a
down-regulation of hepcidin production [44]. The hypoxia
inducible factor/von Hippel-Lindau (HIF/vHL) pathway
mediates responses to hypoxia and other cellular stressors.
In normoxic, iron-suﬃcient conditions, an oxygen and iron-
dependent prolyl hydroxylase modiﬁes the HIF regulatory
subunit named HIF1α. In hypoxia or iron deﬁciency, HIF1α
accumulates, translocates to the nucleus, and associates
with HIF1β, a constitutively expressed HIF subunit. The
HIF heteroduplex binds promoter elements to modulate4 Advances in Hematology
Table 2: A comparison of erythroid pathologies.
Erythroid condition Tissue iron overload Tissue hypoxia Increased erythropoietin Increased erythropoiesis
Ineﬀective erythropoiesis Yes Yes Yes Yes
Hemolysis No Yes Yes Yes
Blood loss No Yes Yes Yes
Iron deﬁciency anemia No Yes Yes No
Aplastic anemia No Yes Yes No
Secondary polycythemia No Yes Yes Yes
Primary polycythemia No No No Yes
gene transcription [51]. Peyssonnauxand colleaguesrecently
demonstrated that mice with liver-speciﬁc, conditional
inactivation of HIF1α maintained on an iron-deﬁcient
diet develop inappropriately high levels of hepcidin [52].
Hypoxia-related changes were not speciﬁcally reported, so
additional studies of this important area of research are
needed. In vitro, inhibition of the prolyl hydroxylases
promotes HIF1α stabilization, and also negatively regulates
hepcidin transcription [53]. Despite the developing body
of evidence in support of a direct role for hypoxia in
hepcidin suppression, there is less consensus as to whether
hepcidin regulation is aﬀected through hypoxia response
elements (HRE), on promoter regions of HIF/vHL pathway-
dependentgenes[52,53].Overall,itisbecomingincreasingly
likely that HIF/vHL participates in hepcidin gene regulation
networks.
A second potential mechanism for hepcidin regulation
by hypoxia involves a protein named hemojuvelin (HJV).
HJV is a member of the repulsive guidance molecule (RGM)
family of proteins that function as coreceptors for Bone
Morphogenetic Protein (BMP) signaling. The membrane
form of HJV binds to type I BMP receptors and stimulates
the BMPs (such as BMP2, 4 or 9) signaling. The signaling
enhances the phosphorylation of SMAD signaling pathway
and stimulates hepcidin transcription [54]. HJV protein
is cleaved and secreted as a soluble form (sHJV) that is
processed by furin-like protease (a proprotein convertase)
[55–57]. sHJV acts as a repressor of BMP signaling by
competing with the membrane form of HJV [58, 59]. Thus,
any stimulus that leads to increased sHJV production may
also reduce hepcidin expression. The generation of sHJV
appears to be increased by iron deﬁciency and hypoxia in
association with the stabilization of HIF1α [57, 58, 60].
Both stimuli may lead to reduced hepcidin production and
increased iron absorption.
Tissue hypoxia may also regulate hepcidin and iron load-
ing indirectly by increasing the expression of the hormone,
EPO. Increased EPO is associated with erythropoietic activ-
ity, which is inversely correlated with hepcidin expression
in patients with thalassemia [61]. Hepcidin was not sup-
pressed if erythropoiesis was inhibited by EPO neutralizing
antibodies, chemotherapy, or irradiation of bone marrow
[62, 63]. However, high doses of EPO directly down-regulate
hepcidin expression in vitro through a mechanism involving
the transcription factor core element binding protein a
(C/EBPa) at a cognate DNA binding site present in the
hepcidin promoter [64]. While the relative contribution of
direct versus indirect EPO eﬀects upon hepcidin regulation
is a matter of ongoing debate, increased expression of EPO is
central to the increase in erythroid demand for iron in both
eﬀective and ineﬀective erythropoiesis.
5.Molecules Releasedfrom Erythroblasts
It is assumed in this review that erythroblasts or the process
of erythropoiesis in the bone marrow of humans includes
some mechanism(s) for communicating the demand for
iron to distant sites in the body. For many years, scien-
tists searched for such a mechanism without satisfaction.
Along with other approaches, the avenue of genomics-
based research was recently utilized for the identiﬁcation
of molecules released from erythroblasts that may serve
as “signals” for iron regulation. Two candidate molecules
(GDF15 and TWSG1) were identiﬁed by this approach. In
addition to these molecules, soluble transferrin receptor has
been explored as a candidate iron regulator.
5.1. Growth Diﬀerentiation Factor 15 (GDF15). Thalassemic
serum contains factors that suppress hepcidin expression
in hepatocytes or hepatocyte cell lines [65]. Based upon
the initial discovery that SMAD4 signal transduction is
involved in hepcidin gene regulation [66], focus was placed
upon signal transduction involving the transforming growth
factor-β (TGF-β) superfamily. Using a transcriptional pro-
ﬁling approach during erythropoiesis, a member of that
superfamilynamedgrowthdiﬀerentiationfactor15(GDF15)
was discovered to be up-regulated in thalassemic serum
and can suppress hepcidin expression in vitro [67]. Inter-
estingly, GDF15 (also called, MIC-1, PLAB, PDF, PTGF-
β, NRG-1, and NAG-1) can be regulated by p53 [68].
Since intramedullary apoptosis is frequently associated with
ineﬀective erythropoiesis, GDF15 was explored as a lead
candidate molecule as a pathological erythroid regulator of
iron. In cultured human hepatocytes and hepatic cell lines,
both recombinant GDF15 as well as GDF15 in the serum
of thalassemia patients inhibited the expression of hepcidin.
Like thalassemia syndromes, congenital dyserythropoietic
anemia type I also showed high levels of serum GDF15
and inappropriate suppression of hepcidin associated with
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was identiﬁed in refractory anemia with ring siderob-
lasts [70]. Interestingly, in vitro studies demonstrated that
erythropoiesis-speciﬁc production of GDF15 was dependent
upon EPO. The production of GDF15 was also stimulated by
a compound that reduces mitochondrial membrane poten-
tial in erythroblasts [70] .T h e s ed a t as u p p o r tac o n c e p tt h a t
apoptotic erythroblasts produce GDF15, and that GDF15
contributes to extra-erythroid tissue iron loading due to
ineﬀective erythropoiesis.
It must be stressed that there is minimal evidence to date
which suggests that GDF15 plays an important role in iron
regulation outside the setting of ineﬀective erythropoiesis.
Lakhal et al. demonstrated up-regulation of GDF15 in
response to iron depletion using intracellular iron chelator
in cell lines and a robust amount of intravenous desferriox-
amine (DFO) in humans. GDF15 up-regulation occurred
independently of HIF signaling, suggesting the involvement
of a novel iron sensing pathway [71]. The study also reported
increased levels of GDF15 in patients with iron deﬁciency.
However, others reported conﬂicting results among blood
donors (see [72]; unpublished data). In separate studies,
Kanda et al. performed an in vivo physiological study of
the relationship between GDF15, serum hepcidin, and ery-
thropoiesis in the clinical setting of stem cell transplantation
(SCT) [73]. The pre- and post-SCT serum hepcidin levels
were monitored along with other factors that may aﬀect hep-
cidin expression. After SCT, serum hepcidin levels showed a
signiﬁcant inverse correlation with markers of erythropoietic
activity, such as the sTfR and the reticulocyte counts, but not
GDF15 levels. Ashby et al. also performed an in vivo study
for physiological erythropoiesis focusing on the relationship
between plasma hepcidin, GDF15, and sTfR. Neither EPO
administration nor venesection caused signiﬁcant changes in
GDF15 or sTfR levels (see below) despite a clear suppression
of hepcidin [74]. Hence, it would surprise the authors
of this review if GDF15 is determined to be the major
erythroid regulator of iron in healthy adult humans. Instead,
these results suggest that GDF15 contributes to hepcidin
suppression and iron overloading in the pathological setting
of ineﬀective erythropoiesis as originally proposed [67].
5.2. Twisted Gastrulation (TWSG1). Erythroblast expression
of a second molecule named twisted gastrulation was
explored as a potential erythroid regulator of hepcidin.
Expression of the TWSG1 gene was discovered as part of
erythroblast transcriptome analyses. Further interest in
this candidate molecule grew from the hypothesis that
TWSG1 may regulate hepcidin in a similar fashion to soluble
hemojuvelin (sHJV). Hemojuvelin has a key role in hepcidin
regulation. Membrane HJV acts as a coreceptor for BMPs,
whereas soluble HJV (sHJV) down-regulates hepcidin in
a competitive way interfering with BMP signaling [57].
The TWSG1 gene product is a small, secreted cysteine-
rich protein that antagonizes the interaction of bone
morphogenetic proteins (BMP) with its receptor [75, 76].
Like sHJV, TWSG1 could suppress hepcidin expression
by interfering with BMP signaling as a BMP antagonist.
In vitro, TWSG1 protein interferes with BMP-mediated
hepcidin expression in human hepatocytes. Phosphorylation
studies further suggest that TWSG1 acts by inhibiting
the BMP-dependent activation of SMAD-mediated signal
transduction. TWSG1 secreted from erythroblasts may thus
contribute to iron loading by inhibiting BMP-mediated
hepcidin expression [77]. Unfortunately, assays are not yet
available to measure the level of TWSG1 in human blood.
Since murine hepatocytes produce BMPs and the major sites
of erythropoiesis in murine thalassemia are the spleen and
liver,itwasproposedthatthiscytokinemaybemoreactivein
hepcidin suppression in the murine model system [78, 79].
5.3. Soluble Transferrin Receptor (sTfR). Approximately 80%
of soluble TfR1 (sTfR) is generated during the maturation
of erythroid cells [80]. Soluble TfR is a truncated form of
the TfR on the surface of the cells [81]. The sTfR level
indicates erythropoietic activity and iron status of the organs
[82].sTfRisincreasedinthalassemia[67],congenitaldysery-
thropoietic anemia [69, 81], and sideroblastic anemia [83].
All of these observations make sTfR a strong candidate for
erythroid regulation of hepcidin and iron. However, it was
concluded on the basis of a transgene expression model in
mice that sTfR levels neither regulate hepcidin nor iron [84].
6. Summary
The phrase “ineﬀective erythropoiesis” collectively describes
a group of erythroid defects that are marked by decreased
erythrocyte production despite increased early erythro-
poiesis. Ineﬀective erythropoiesis manifests a unique feature
ofnon-transfusionalironoverloadinextra-erythroidtissues.
This feature of secondary hemochromatosis distinguishes
ineﬀective erythropoiesis from other causes of anemia.
Further, the excess iron accumulates in parenchymal cells
and negatively aﬀects clinical outcome [85]. As such, the
regulation of iron loading and overloading in ineﬀective
erythropoiesis remains a fertile area of basic and clinical
research. Physiological mechanisms that regulate iron in
the context of hemoglobin production and catabolism are
likely involved in both eﬀective (normal) and ineﬀective
erythropoiesis. In this review, we proposed that additional
mechanisms or signals related to the erythroid pathol-
ogy may contribute to iron overloading in other tissues.
Increased expression of GDF15 from apoptotic erythroblasts
is being explored in this context. Based upon the rapid
pace of discovery within the ﬁeld of iron biology, additional
mechanisms and insights regarding the special relationships
between erythropoiesis and iron regulation are predicted.
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